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Epithelial to mesenchymal transition (EMT) is an important mechanism for the initial step of
metastasis. Proteomic analysis indicates that Pirin is involved in metastasis. However, there are
no reports demonstrating its direct contribution. Here we investigated the involvement of Pirin
in EMT. In HeLa cells, Pirin suppressed E-cadherin expression and regulated the expression of other
EMT markers. Furthermore, cells expressing Pirin exhibited a spindle-like morphology, which is
reminiscent of EMT. A Pirin mutant defective for Bcl3 binding decreased E-cadherin expression
similar to wild-type, suggesting that Pirin regulates E-cadherin independently of Bcl3-Slug
signaling. These data provide direct evidence that Pirin contributes to cancer metastasis.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tumor cell metastasis is responsible for approximately 90% of
the deaths related to cancer [1]. The metastatic process appears
to follow two prominent stages: cancer cells ﬁrst migrate from
the primary tumor into the surrounding tissues as well as the
microvasculature of the lymph and blood systems; then, the cells
exit the bloodstream invading new tissues and form secondary
tumors [1,2]. The invasive and migratory capabilities of carcinoma
cells requires a loss of cell adhesion and increased cell mobility,
collectively known as epithelial to mesenchymal transition (EMT)
[1,3]. EMT is a cellular process, which converts immotile epithelial
cells to motile mesenchymal cells by disrupting cell adhesion
through the repression of E-cadherin, a cell–cell adhesion protein.
EMT was ﬁrst recognized to play a role in embryological develop-
ment [4], but recent studies have revealed its signiﬁcance in cancer
[5]. Speciﬁcally, decreased membrane localization of E-cadherin
accelerates the development of metastatic carcinomas in a variety
of in vitro and in vivo models [6–9]. The following major changes
occur during EMT: (i) epithelial cells undergo morphologicalchanges from having a cobblestone appearance to cells that are
spindled and resemble those of a mesenchymal origin; (ii) cell–cell
adhesion is lost; (iii) epithelial marker genes, such as E-cadherin
and Occludin, are downregulated and mesenchymal marker genes,
including N-cadherin, Vimentin and Fibronectin, are upregulated;
and (iv) cells acquire the ability to invade and migrate [3,10,11].
In addition, cells having undergone EMT exhibit cancer drug resis-
tance [12–14]. Therefore, EMT plays a crucial role in the malignant
progression of cancer.
Pirin is highly conserved between mammals, plants, fungi, and
prokaryotes [15]. While the function of human Pirin is poorly
understood, Pirin homologs are known to regulate many biological
processes [16–20]. For instance, the Arabidopsis Pirin homolog
AtPirin1 is involved in seed germination and early seed develop-
ment [18]. The tomato homolog Le-Pirin is upregulated during pro-
grammed cell death [19]. Furthermore, structural analysis of
YhhW, the Pirin homolog in Escherichia coli, revealed a putative
quercetin 2,3-dioxygenase activity [20]. Nevertheless, the biologi-
cal importance of Pirin in mammalian cells remains uncertain.
Associations have been made between human Pirin and cancer
malignancies [21–24]. The inﬂuence Pirin has on cancer malignan-
cy is dependent on its function as a transcriptional coregulator
[15,25,26] interacting with the Bcl3-NF-jB (p50) complex
[25,27]. Bcl3 is a known regulator of cell survival, proliferation,
and cancer malignancy in many tumor cell lines [28–30]. There-
fore, the interaction between Pirin and Bcl3 may enhance NF-jB
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(TPh A), a Pirin-speciﬁc inhibitor, reduces the binding afﬁnity of
Pirin for Bcl3, Slug expression, and subsequent cell migration in
melanoma [31]. A proteomics analysis of adenoid cystic tumor
metastases also suggest that Pirin is involved in cancer progression
[23], but the mechanism and functional roles of Pirin in metastasis
remain unknown.
In this study, we investigated the function of Pirin during
metastasis and demonstrated that it regulates EMT by decreasing
the expression of E-cadherin. We also demonstrated that Pirin
inﬂuences cancer progression by contributing to cell migration
and drug resistance. These data indicate that Pirin regulates cancer
metastasis by inducing EMT and may be a suitable cancer therapy
target.2. Experimental procedures
2.1. Cell culture and reagents
Human cervical carcinoma HeLa cells and human embryonic
kidney 293T cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 5% (v/v) fetal bovine serum,
100 units/ml penicillin G, 100 mg/l kanamycin, 600 mg/l
L-glutamine and 2.25 g/l NaHCO3 at 37 C in a humidiﬁed incubator
with 5% CO2.
2.2. Knockdown of Pirin
Cells were transfected with 10 nM of each siRNA using
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA). The sequences
of siRNAs were as follows: siCTRL, 50-CGUACGCGGAUACUUC-
GAdTdT-30; siPirin#1, 50-AGAGAUUUCUCAAGCUAUUdTdT-30;
siPirin#2, 50-GAAGCCACUUUGUCUUAAUdTdT-30. siGFP (Silencer
GFP siRNA; #AM4626) was purchased from Applied Biosystems
(Foster City, CA).
2.3. Semi-quantitative RT-PCR
To perform semi-quantitative RT-PCR, we made slight modiﬁca-
tions to a previously described method [32,33]. cDNAs were used
for PCR ampliﬁcation with EmeraldAmp PCR Master Mix (Takara
Bio Inc., Shiga, Japan). The sequences of the primers used for
semi-quantitative RT-PCR were as follows: Pirin, 50-ACCCAGGAGCC
AAACATTCC-30 (forward) and 50-TTCCAGGTTTTGGCCCTTTC-30
(reverse); E-cadherin, 50-ACCAGAATAAAGACCAAGTGACCA-30 (for-
ward) and 50-AGCAAGAGCAGCAGAATCAGAAT-30 (reverse);
Occludin, 50-ACAGTCCCATGGCATACTCT-30 (forward) and 50-GATA
TTCCCTGATCCAGTCCTC-30 (reverse); Fibronectin, 50-GCTCATCATC
TGGCCATTTT-30 (forward) and 50-ACCAACCTACGGATGACTCG-30
(reverse); N-cadherin, 50-GGAGAAGAAGACCAGGACTATG-30 (for-
ward) and 50-CTCACCACCACTACTTGAGGA-30 (reverse); Vimentin,
50-GAGATGCTTCAGAGAGAGGAAG-30 (forward) and 50-AGAGAGG
TCAGCAAACTTGG-30 (reverse); GFP, 50-GGCAATAAGATGGAGTACA
ACTAC-30 (forward) and 50-AAGCCGAAGTAGATCATGTG-30
(reverse); GAPDH, 50-GATTCCACCCATGGCAAATTC-30 (forward)
and 50-CACGTTGGCAGTGGGGAC-30 (reverse).
2.4. Western blot
Cells were lysed by sonication at 4 C in lysis buffer (50 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 0.1% (w/v) SDS, 1% (v/v) Triton
X-100, 1% (w/v) sodium deoxycholate, and 1 mM phenylmethyl-
sulfonyl ﬂuoride). The lysates were centrifuged at 14000 rpm for
10 min, and the protein concentration of each lysate was measured
by staining with Coomassie Brilliant Blue (CBB) G-250 (Bio-RadLaboratories, Inc., Hercules, CA). Lysates were boiled in loading
buffer (350 mM Tris–HCl, pH 6.8, 30% (w/v) glycerol, 0.012%
(w/v) bromophenol blue, 6% (w/v) SDS, and 30% (v/v) 2-mercap-
toethanol) for 5 min and separated in SDS–polyacrylamide gels
by electrophoresis. Proteins were transferred to PVDF membranes
and immunoblotted with anti-Pirin (Abcam, Cambridge, UK;
#ab55978), anti-E-cadherin (Beckton-Dickinson, Franklin Lakes,
NJ; #08626), anti-GFP (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA; #sc-9996), anti-GST (Santa Cruz Biotechnology, Inc.; #sc-138),
and anti-a-tubulin (Sigma Aldrich, St. Louis, MO; #T5168) antibod-
ies. Detection of antibody was achieved with an enhanced chemi-
luminescence reagent (Immobilon Western Chemiluminescent
HRP Substrate, Millipore Corporation, Bedford, MA) using the
ImageQuantLAS 4000mini (GE Healthcare, Buckinghamshire, UK).2.5. Construction of expression vectors
The cDNA encoding human Bcl3 (ankyrin repeat domain, ARD)
was ampliﬁed from a HeLa cell cDNA library and subcloned into
the pGEX-6P-1 vector (GE Healthcare). The cDNA encoding human
Pirin was ampliﬁed from a human ﬁbrosarcoma HT1080 cell cDNA
library and subcloned into the pAcGFP-N1 (Clontech, Palo Alto, CA)
or pET-41a(+) (Millipore Corporation) vector. The Pirin/E103A
mutant containing a Glutamic acid for Alanine substitution at
residue 103 was generated by PCR site-directed mutagenesis. The
E-cadherin regulatory sequence located 995 bp upstream of the
transcriptional start site was ampliﬁed from human genomic
DNA by PCR, and subcloned into the pGL3-basic vector (Promega,
Madison, WI). A series of promoter deletion mutants (795  +1,
565  +1, 365  +1, 175  +1) were also generated by PCR
using various 50 primers and a ﬁxed 30 primer. The sequences of
these primers were as follows: 995, 50-TTTTGGTACCGCCGCT
CGAGGCAGAGTGCAGTGGC-30; 795, 50-TTTTGGTACCGTCTCTTGA
ACCCGGCAGGCGGAGG-30; 565, 50-TTTTGGTACCATACAGGGAGAC
ACAGCGCCCCCAC-30; 365, 50-TTTTGGTACCTTGGGTGAAAGAGTG
AGACCCCATC-30; 175, 50-TTTTGGTACCAGGCTAGAGGGTCACCGC
GTCTATG-30; 30 primer, 50-TTTTAGATCTCGAGCCCTGAGAGGGGG
TGCGTGGC-30.
2.6. Pirin-expressing cell lines
The stable cell lines expressing Pirin-GFP or GFP were estab-
lished using limited dilution technique. The expression vectors
were transfected into HeLa cells and selected for transformation
with 400 lg/ml G418 (Roche Applied Science, Basel, Switzerland).
The cells expressing high levels of Pirin-GFP or GFP were designat-
ed HeLa/Pirin-GFP and HeLa/GFP, respectively.
2.7. Quantitation of changes to cell morphology
Cells were observed with an EVOS microscope (Life technolo-
gies, Carlsbad, CA) and photographed to evaluate morphological
changes. Changes to cell morphology were determined by measur-
ing the percent circularity [34], {4p(area)/(perimeter)2}  100,
with Image J software. The percent circularity decreases when
epithelial cells take on a mesenchymal cell morphology [35,36].
2.8. Wound healing assay
To perform wound healing assay, we used slightly modiﬁed ver-
sion of previously described method [37]. HeLa cells in 12-well
plates were allowed to reach conﬂuence before the surface was
uniformly scratched across the center of each well with a tip. The
wells were then rinsed twice with phosphate-buffered saline
(PBS), after which the cells were replenished with growth media
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2.9. GST pull-down assay
To assay in vitro binding, 14 pmol of GST and GST-Bcl3/ARD
puriﬁed from E. coli was conjugated to Glutathione-Sepharose 4B
(GE Healthcare) in binding buffer (10 mM Tris–HCl, pH 7.5,
50 mM KCl, 5 mM MgCl2, 1 mM EDTA, 0.1% (w/v) Nonidet P-40).
Then, 30 pmol of puriﬁed His6-Pirin or His6-Pirin(E103A) was
incubated with the beads for 2 h at 4 C. The beads were washed
three times in binding buffer and boiled. Samples were separated
by SDS–PAGE and detected by Western blot.
2.10. Luciferase reporter assay
293T cells were plated in 24-well plates. After 24 h, cells were
transiently transfected with 100 ng of Pirin-GFP or GFP expression
plasmids, 100 ng of construct expressing E-cadherin promoter, and
5 ng of phRL-TK vector (Promega). HeLa cells were plated in
12-well plates, and after 24 h, cells were transiently transfected
with 250 ng of Pirin-GFP or GFP expression plasmids, 250 ng of
construct expressing E-cadherin promoter, and 10 ng of phRL-TK
vector. HeLa cells transfected with siRNAs targeting GFP or Pirin
were plated in 12-well plates and then transiently transfected
24 h later with 500 ng of construct expressing E-cadherin promoter
and 10 ng of phRL-TK vector. Cells were lysed 24 h after transfec-
tion and the luciferase activity was measured, normalized to
Renilla luciferase activity and subtracted the normalized value of
the luciferase activity of empty vector.
2.11. Statistical analysis
Statistical analyses were performed using two-tailed Student’s
t-test. All results are the calculated mean of each experiment.
Signiﬁcance was set at P < 0.05 (⁄).A
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3.1. Pirin regulates the expression of E-cadherin and EMT markers
In melanoma, Pirin enhances NF-jB activity and increases Slug
expression by binding Bcl3 [31], and it may also be involved in ade-
noid cystic tumor metastasis [23]. Since Slug suppresses E-cadher-
in transcription and is recognized as a major EMT inducer, we
hypothesized that Pirin may regulate EMT through inducing Slug
expression. To investigate whether Pirin regulates EMT, we
measured E-cadherin expression following Pirin knockdown. As
shown in Fig. 1A and B, E-cadherin expression was signiﬁcantly
increased following Pirin knockdown indicating that it may pro-
mote EMT. To conﬁrm this, we established Pirin-expressing HeLa
cells (Fig. 1C), which inhibited the expression of E-cadherin
(Fig. 1D). Additionally, the expression of Occludin, an epithelial
marker, was decreased, and several mesenchymal markers, includ-
ing Fibronectin, N-cadherin, and Vimentin, were increased by Pirin
expression (Fig. 1D). These data suggest that Pirin promotes EMT.
3.2. Pirin induces EMT-associated cell morphological changes
As mentioned above, cells undergo morphological changes dur-
ing EMT. Therefore, we next analyzed whether Pirin expression
affects cell morphology. Quantitative analysis of morphological
changes was based on cell circularity, {4p(area)/(perimeter)2} -
 100, which decreases during EMT-associated morphological
changes [34–36]. Indeed, TGF-b or TNF-a exposure induced EMT-
associated cell morphological changes in HeLa cells (data not
shown). Employing this parameter of circularity, we compared
the morphology of our established HeLa/Pirin-GFP cells with con-
trol HeLa/GFP cells. Although the control HeLa/GFP cells displayed
a cobblestone-like morphology, HeLa/Pirin-GFP cells were elongat-
ed in shape (Fig. 2A). Indeed, compared with control cells, the cir-
cularity of HeLa/Pirin-GFP cells was signiﬁcantly decreased
(Fig. 2B). To conﬁrm that these observations were dependent on
Pirin expression, HeLa/Pirin-GFP cells were treated with an siRNAB
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morphology (Fig. 2C) and circularity (Fig. 2D) when treated with
Pirin siRNA indicating that Pirin expression induces EMT.
3.3. Pirin induces cell migration
During EMT cells acquire migratory capabilities. Therefore, we
analyzed whether Pirin affects cell migration. HeLa cells were
treated with an siRNA targeting Pirin and migration was assessed
using a wound healing assay. Although Pirin knockdown had no
effect on cell proliferation (data not shown), wound repair was
inhibited in Pirin-depleted HeLa cells (Fig. 3A and B) suggesting
that Pirin promoted cell migration. Furthermore, camptothecin
treatment of HeLa/GFP cells caused decreased cell viability in a
dose-dependent manner, whereas HeLa/Pirin-GFP cells were more
resistant to drug treatment (data not shown). These results suggest
that Pirin induces EMT-like phenotypes, such as cell migration and
anticancer drug resistance.
3.4. Pirin regulates EMT independently of Bcl3-Slug signaling
To investigate whether Pirin controls E-cadherin expression at
the transcriptional level, we measured E-cadherin promoter activ-
ity with a reporter assay. Indeed, the luciferase reporter analysis
indicated that Pirin inhibited E-cadherin promoter activity
(Fig. 4A and B). To determine if Bcl3 is involved in Pirin-induced
EMT, we tested whether a Pirin mutant defective in Bcl3 binding
could inhibit E-cadherin expression. We generated a mutation in
the metal-binding cavity of Pirin(E103A) and conﬁrmed that it dis-
rupted Bcl3 binding. In vitro GST pull-down analysis using recom-
binant Pirin and Bcl3/ARD demonstrated that the Pirin mutant was
defective for Bcl3 binding compared to wild-type (Fig. 5A). Inter-
estingly, expression of both wild-type Pirin and the mutant defec-
tive in Bcl3 binding reduced E-cadherin gene and protein
expression (Fig. 5B and C). Taken together these results indicatethat Pirin decreases E-cadherin expression without binding Bcl3,
and suggest that Pirin regulates EMT independently of Bcl3-Slug
signaling.
4. Discussion
A characteristic feature of EMT is the disruption of epithelial
cell–cell contact, which is achieved by reduced E-cadherin expres-
sion. Therefore, revealing the regulatory pathways controlling
E-cadherin expression may elucidate the mechanisms of EMT.
Several transcription factors regulate E-cadherin transcription.
For instance, Snail, Slug, Twist, and Zeb act as master transcription-
al regulators that bind the consensus E-box sequence in the
E-cadherin gene promoter and decrease the transcriptional activity
[38]. Since Pirin regulates the transcription of Slug [31], we
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demonstrated that Pirin decreases E-cadherin expression, and
induces EMT and cancer malignant phenotypes. Since EMT is an
initial step of metastasis, Pirin may contribute to cancer
progression.
We next examined whether the regulation of EMT by Pirin is
attributed to Bcl3 binding and the induction of Slug. To this end,
we generated a Pirin mutant (E103A) defective for Bcl3 binding
(Fig. 5A). Single Fe2+ ion chelating is coordinated by His56, His58,
His101, and Glu103 of Pirin, and the N-terminal domain containingA
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GFP. Cells were lysed 48 h after transfection and lysates were analyzed by Western blot (B
gene (C).these residues is highly conserved between mammals, plants,
fungi, and prokaryotic organisms [15,27]. Therefore, it has been
predicted that this N-terminal domain containing the metal-bind-
ing cavity is important for Pirin function [20,26,31]. Indeed, TPh A
inserts into the metal-binding cavity and inhibits binding to Bcl3
suggesting that the interaction occurs with the metal-binding cav-
ity of Pirin [31]. In contrast, Hai Pang suggests that a Pirin–Bcl3–
(p50)2 complex forms between acidic regions of the N-terminal
Pirin domain at residues 77–82, 97–103 and 124–128 with a basic
patch of Bcl3 [27]. In this study, we mutated Glutamic acid 103, a
residue common between Hai Pang’s model and Pirin’s metal-
binding cavity. Pull-down analysis indicated that an E103A mutant
is defective in for Bcl3 binding (Fig. 5A). This is the ﬁrst experimen-
tal demonstration showing that Glu103 of Pirin is important Bcl3
binding. However, expression of the E103A mutant suppressed E-
cadherin gene expression similarly to wild-type Pirin (Fig. 5B and
C). Although the Bcl3–(p50)2 complex participates in oncogene
addiction in cervical cells [39,40], expression of Pirin in HeLa cells
did not increase Slug expression (data not shown). Therefore, we
conclude that Pirin decreases E-cadherin expression independently
of Bcl3-Slug signaling.
To understand how Pirin suppresses E-cadherin gene expres-
sion, we analyzed E-cadherin promoter activity (Fig. 4). Since Pirin
decreased the activity of the E-cadherin promoter (995  +1), we
constructed a series of promoter deletion mutants (795  +1,
565  +1, 365  +1, 175  +1) to identify a region important
for Pirin-mediated regulation. Expression of Pirin decreased the
transcriptional activity of all constructs (Supplementary Fig. S1A),
suggesting that Pirin may suppress E-cadherin expression through
element(s) in region 175  +1. Yan-Nan Liu and colleagues
proposed that this region contains four Sp1-binding sites andST-Bcl3/ARD
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). RNA collected at 48 h was used for RT-PCR with the speciﬁed primer sets for each
K. Komai et al. / FEBS Letters 589 (2015) 738–743 743two E-boxes that regulate E-cadherin expression (Supplementary
Fig. S1B) [41]. Further analysis is required to determine whether
of Pirin suppresses E-cadherin through these regulatory elements.
In conclusion, we demonstrated that Pirin decreases E-cadherin
gene expression at the transcriptional level and contributes to EMT
and cancer malignancy. Furthermore, we showed that Pirin-medi-
ated E-cadherin inhibition is independent of Bcl3-Slug signaling
using a Pirin mutant defective for Bcl3 binding. This provides
new insight into the underlying mechanism by which Pirin con-
tributes to metastasis and may inﬂuence the design of better can-
cer therapies.
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